H.C. Wainwright lowered the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $110 from $125 and keeps a Buy rating on the shares, reflecting adjustments to the firm’s long-term sales ramp expectations after Rhythm recently announced its Q4 results and announced additional positive data from its global Phase 3 TRANSCEND trial of setmelanotide in patients with acquired hypothalamic obesity.

Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions

Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on RYTM:

Disclaimer & DisclosureReport an Issue

Rhythm Highlights Positive Phase 3 Data in Hypothalamic Obesity

Rhythm Pharmaceuticals price target lowered to $140 from $141 at Canaccord

Rhythm announces additional data from Phase 3 trial of setmelanotide

Rhythm Pharmaceuticals price target raised to $143 from $140 at Guggenheim

Rhythm Pharmaceuticals price target lowered to $136 from $145 at Wells Fargo